[Skip to Content]
[Skip to Content Landing]
October 2015

Reduced Risk of Squamous Cell Carcinoma With Adequate Treatment of Vulvar Lichen Sclerosus

Author Affiliations
  • 1Department of Dermatology, Oxford University Hospitals Trust, Oxford, England
  • 2Department of Dermatology, P. D. Hinduja National Hospital and Medical Research Center, Mumbai, India
  • 3Department of Dermatology, Sir HN Reliance Foundation Hospital, Mumbai, India
  • 4Department of Obstetrics and Gynecology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire
  • 5Department of Surgery (Dermatology), Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire
JAMA Dermatol. 2015;151(10):1059-1060. doi:10.1001/jamadermatol.2015.0644

In this issue, Lee and colleagues1 present the results of the largest prospective clinical cohort study to date concerning 507 women with vulvar lichen sclerosus (VLS). The authors present evidence that poor compliance with topical corticosteroid (TCS) treatment predisposes patients to the development of vulvar cancer and scarring. They propose that initial treatment regimens should be selected using a variety of corticosteroid potencies based on the severity of signs at presentation. They also propose that maintenance treatment for VLS should be the norm, increasing or decreasing the potency of treatment as necessary. The authors recommend life-long specialist follow-up.

First Page Preview View Large
First page PDF preview
First page PDF preview